Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using 67 Cu-2IT-BAT-Lym-1 Radioimmunotherapy
2001
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2011
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
2000 Standout
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
Improving the efficacy of antibody-based cancer therapies
2001
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Contribution of platelets to tumour metastasis
2011 Standout
Prognosis of Cancers Associated with Venous Thromboembolism
2000 Standout
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
1999
Therapeutic cancer targeting peptides
2002
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Cancer Statistics, 2006
2006 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
1992
Monoclonal antibodies: versatile platforms for cancer immunotherapy
2010
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
1995 Standout
Follicular B helper T cells in antibody responses and autoimmunity
2005
Antibody therapy of cancer
2012 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma
2007
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2005
Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal
2005
Signaling antibodies in cancer therapy
1999
Treating metastatic cancer with nanotechnology
2011
Radioimmunotherapy for Non-Hodgkin's Lymphoma
2005
Malignancy, thrombosis and Trousseau: the case for an eponym
2003
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
2011
Molecular mechanisms of T cell co-stimulation and co-inhibition
2013 Standout
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
1997 Standout
Clinical trials of antibody therapy
2000
Hematopoietic Stem-Cell Transplantation
2006 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Chemistry in living systems
2005 StandoutNobel
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
2002
Immunotherapy: past, present and future
2003
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
IgG4-related disease
2014 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2003 Standout
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2004
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Occult cancer in patients with deep venous thrombosis. A systematic approach
1991
The fusion of anatomic and physiologic imaging in the management of patients with cancer
2001
Review of clinical radioimmunotherapy
2006
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
2003
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Antibody therapy of lymphoma
2001
Monoclonal antibodies for cancer immunotherapy
2009
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Radioimmunotherapy
2001
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
2003
Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
2005
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Carbon quantum dots and their applications
2014 Standout
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
2002 Standout
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma
1999
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients
2003
Effective Cancer Therapy Through Immunomodulation
2005
IL-17 and Th17 Cells
2009 Standout
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
1998
Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels
2017 StandoutNobel
Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
2004
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
2002
Drug Discovery: A Historical Perspective
2000 StandoutScience
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
2008
Monoclonal Antibody Therapy for Cancer
2003
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
1997
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
2003
Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
2006
Diffuse large cell lymphoma
2011
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
2008
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
1999
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
2003
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
Combined 90Yttrium‐DOTA‐labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
2004
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Tumor Immunology
1998
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
2002
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
2003
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
2005
Elicitation of structure-specific antibodies by epitope scaffolds
2010 StandoutNobel
Works of Judith Estes being referenced
Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
1996
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
2005
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
2000
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
2000
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
1998
PROGNOSIS IN IDIOPATHIC THOMBOPHLEBITIS
1951